argenx SE (ARGX.BR)
EUR 575.6
(1.34%)
EUR 575.6
(1.34%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.13 Billion EUR | 176.16% |
| 2022 | 410.74 Million USD | -17.4% |
| 2021 | 497.27 Million USD | 1009.97% |
| 2020 | 44.8 Million EUR | -42.69% |
| 2019 | 78.16 Million EUR | 218.1% |
| 2018 | 24.57 Million EUR | -43.75% |
| 2017 | 43.68 Million EUR | 182.33% |
| 2016 | 15.47 Million EUR | 106.49% |
| 2015 | 7.49 Million EUR | 64.07% |
| 2014 | 4.56 Million EUR | 23.56% |
| 2013 | 3.69 Million EUR | 69.3% |
| 2012 | 2.18 Million EUR | 49.75% |
| 2011 | 1.45 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 477.63 Million EUR | 118.77% |
| 2024 Q1 | 401 Million USD | -1.58% |
| 2023 Q3 | 329.78 Million USD | 21.9% |
| 2023 Q1 | 219.14 Million USD | 25.83% |
| 2023 Q2 | 270.55 Million USD | 23.46% |
| 2023 FY | 1.13 Billion EUR | 176.16% |
| 2023 Q4 | 406.83 Million USD | 23.36% |
| 2022 FY | 410.74 Million USD | -17.4% |
| 2022 Q3 | 137.98 Million USD | 83.5% |
| 2022 Q4 | 174.16 Million USD | 26.22% |
| 2022 Q1 | 23.41 Million USD | -10.03% |
| 2022 Q2 | 75.19 Million USD | 221.18% |
| 2021 Q1 | 158.15 Million EUR | 1026.7% |
| 2021 FY | 497.27 Million USD | 1009.97% |
| 2021 Q2 | 312.24 Million USD | 97.43% |
| 2021 Q3 | 857 Thousand USD | -99.73% |
| 2021 Q4 | 26.02 Million USD | 2936.41% |
| 2020 Q4 | 14.03 Million EUR | 0.0% |
| 2020 FY | 44.8 Million EUR | -42.69% |
| 2020 Q2 | 22.38 Million EUR | 0.0% |
| 2019 Q1 | 40.93 Million EUR | 2779.29% |
| 2019 FY | 78.16 Million EUR | 218.1% |
| 2019 Q4 | 17.51 Million EUR | 100.63% |
| 2019 Q3 | 8.73 Million EUR | 2.02% |
| 2019 Q2 | 8.55 Million EUR | -79.09% |
| 2018 Q2 | 13.84 Million EUR | 101.54% |
| 2018 Q3 | 2.44 Million EUR | -82.34% |
| 2018 FY | 24.57 Million EUR | -43.75% |
| 2018 Q1 | 6.86 Million EUR | -33.43% |
| 2018 Q4 | 1.42 Million EUR | -41.83% |
| 2017 Q1 | 7.11 Million EUR | 93.52% |
| 2017 Q2 | 18.56 Million EUR | 160.87% |
| 2017 Q4 | 10.31 Million EUR | 34.09% |
| 2017 Q3 | 7.69 Million EUR | -58.56% |
| 2017 FY | 43.68 Million EUR | 182.33% |
| 2016 Q3 | 5.5 Million EUR | 45.64% |
| 2016 Q1 | 2.51 Million EUR | 32.96% |
| 2016 FY | 15.47 Million EUR | 106.49% |
| 2016 Q2 | 3.77 Million EUR | 50.51% |
| 2016 Q4 | 3.67 Million EUR | -33.21% |
| 2015 Q2 | 1.72 Million EUR | 31.8% |
| 2015 FY | 7.49 Million EUR | 64.07% |
| 2015 Q4 | 1.88 Million EUR | -26.43% |
| 2015 Q3 | 2.56 Million EUR | 48.66% |
| 2015 Q1 | 1.31 Million EUR | -26.42% |
| 2014 Q2 | 308.66 Thousand EUR | -34.19% |
| 2014 Q3 | 2 Million EUR | 550.83% |
| 2014 Q4 | 1.78 Million EUR | -11.35% |
| 2014 FY | 4.56 Million EUR | 23.56% |
| 2014 Q1 | 468.98 Thousand EUR | -49.81% |
| 2013 Q2 | 530.61 Thousand EUR | -5.18% |
| 2013 Q3 | 1.67 Million EUR | 215.1% |
| 2013 Q4 | 934.37 Thousand EUR | -44.12% |
| 2013 Q1 | 559.62 Thousand EUR | 0.0% |
| 2013 FY | 3.69 Million EUR | 69.3% |
| 2012 FY | 2.18 Million EUR | 49.75% |
| 2011 FY | 1.45 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Nicox S.A. | 257 Thousand EUR | -441264.233% |
| European Medical Solutions | 40.56 Million EUR | -2696.337% |
| FERMENTALG | 4.05 Million EUR | -27859.233% |
| BioSenic S.A. | 543 Thousand EUR | -208796.147% |
| Celyad Oncology SA | 102 Thousand EUR | -1111964.782% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -54251.034% |
| Onward Medical N.V. | 532 Thousand EUR | -213115.428% |
| Oxurion NV | 263 Thousand EUR | -431195.087% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -85443.445% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 78.402% |